{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001357","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.068751+00:00","generated_at":"2026-06-05T02:30:26.929548+00:00","sec_items":["1.01","3.02","5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sunshine Biopharma CEO buys voting-preferred shares for $10K; 1-for-200 reverse split approved","bullets":["CEO Steve Slilaty purchased 100,000 Series B Preferred shares for $10,000, each with 1,000 votes.","Preferred stock is non-convertible, non-redeemable, with $0.10 liquidation preference superior to common.","Slilaty, holder of ~57.4% voting power, approved by written consent a reverse stock split up to 1-for-200.","Reverse split up to 1-for-200 aims to regain Nasdaq $1.00 minimum bid; effective 20 days after mailing info statement filed March 5."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001357","json":"https://secwatch.observer/filing/0001683168-24-001357.json","markdown":"https://secwatch.observer/filing/0001683168-24-001357.md","text":"https://secwatch.observer/filing/0001683168-24-001357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/0001683168-24-001357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:30:26.929548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"550a9adb76466965fff643844a4c9a8cdba654e1","claim":"Sunshine Biopharma Inc. shareholders approved Reverse stock split of the Company’s common stock at a ratio up to 1-for-200 at the 2024-03-04 meeting.","evidence_excerpt":"On March 4, 2024, Dr. Slilaty, as the holder of the majority of the voting power of the stockholders of the Company, approved by written consent to effect a reverse stock split of the Company’s common stock at a ratio up to 1-for-200.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/0001683168-24-001357-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}